Mode
Text Size
Log in / Sign up

Higher BUN/Cr ratio linked to increased mortality in older patients with sepsis-associated AKI

Higher BUN/Cr ratio linked to increased mortality in older patients with sepsis-associated AKI
Photo by Zulfugar Karimov / Unsplash
Key Takeaway
Consider BUN/Cr ratio as a potential prognostic marker in older patients with sepsis-associated AKI, pending prospective validation.

A retrospective cohort study at Henan Provincial People’s Hospital analyzed 764 patients aged ≥50 years with sepsis-associated acute kidney injury (SA-AKI). The study examined the association between blood urea nitrogen to creatinine ratio (BUN/Cr) and mortality, comparing patients by BUN/Cr tertiles (T1: ≤16.00, T2: 16.01–22.50, T3: >22.50).

Each 1-unit increase in BUN/Cr was associated with higher all-cause mortality at 28 days (HR 1.039, 95% CI 1.014–1.064; absolute mortality 5.0%), 90 days (HR 1.038, 95% CI 1.020–1.055; absolute mortality 11.4%), and 1 year (HR 1.027, 95% CI 1.013–1.041; absolute mortality 22.3%). Patients in the highest tertile (T3) had significantly higher mortality risks compared to the lowest tertile (T1) at 90 days (HR 3.042, 95% CI 1.742–5.312) and 1 year (HR 1.971, 95% CI 1.349–2.879).

The BUN/Cr ratio demonstrated moderate predictive ability for mortality, with area under the curve values of 0.636 for 28-day, 0.656 for 90-day, and 0.610 for 1-year mortality. Adverse events were not reported in this analysis.

Key limitations include the retrospective, single-center design and lack of reported safety data. The study population was limited to patients aged ≥50 years from one Chinese hospital. While these findings suggest BUN/Cr may be a prognostic marker in SA-AKI, they represent observational associations that require prospective validation before influencing clinical practice.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
ObjectiveTo investigate the association between the blood urea nitrogen to creatinine ratio (BUN/Cr) and all-cause mortality in sepsis-associated acute kidney injury (SA-AKI) patients aged ≥ 50 years.MethodsThis single-center, retrospective cohort study included 764 patients aged ≥ 50 years with SA-AKI hospitalized at Henan Provincial People’s Hospital from January 2020 to August 2024. Patients were grouped into BUN/Cr tertiles: T1 (≤ 16.00), T2 (16.01–22.50), and T3 (> 22.50). The primary outcomes were 28-day, 90-day, and 1-year all-cause mortality. Associations between BUN/Cr and mortality were evaluated using Cox regression and subgroup analyses. Predictive value and dose-response relationships were assessed via receiver operating characteristic (ROC) curves and restricted cubic spline (RCS) models.ResultsIn the overall cohort, the all-cause mortality rates at 28 days, 90 days, and 1 year were 5.0%, 11.4%, and 22.3%, respectively. After adjusting for confounders, each 1-unit increase in BUN/Cr was linked to higher mortality at 28 days (HR = 1.039, 95% CI: 1.014–1.064), 90 days (HR = 1.038, 95% CI: 1.020–1.055), and 1 year (HR = 1.027, 95% CI: 1.013–1.041). A 1-standard deviation increase in BUN/Cr corresponded to a 45.0%, 43.6%, and 29.4% increased risk at each time point (all P < 0.05). Compared with the T1 group, patients in the T3 had significantly higher risks of 90-day (HR = 3.042, 95% CI: 1.742–5.312) and 1-year (HR = 1.971, 95% CI: 1.349–2.879) mortality. Subgroup analyses confirmed consistent associations between BUN/Cr and 90-day and 1-year mortality across various clinical subgroups. ROC curve analysis demonstrated that BUN/Cr had a moderate predictive ability for mortality at 28 days (AUC = 0.636), 90 days (AUC = 0.656), and 1 year (AUC = 0.610). Notably, adding BUN/Cr to the baseline multivariable model significantly improved discrimination for 28-day mortality (P for comparison = 0.012). RCS modeling showed a linear and positive association between BUN/Cr and mortality without significant non-linearity (P-nonlinear > 0.5 for all time points).ConclusionA higher BUN/Cr ratio is significantly linked to increased short- and long-term mortality in SA-AKI patients aged 50 and above, suggesting its potential utility for early risk stratification and clinical decision-making.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.